![]() More than half of the patients (58%) in this analysis who reported pain at the start of the study experienced a clinically meaningful pain response during treatment.Īny-grade drug-related treatment-emergent adverse events (AEs) occurred in 32% of patients, whereas AEs considered severe or worse were observed in 10% of patients. ![]() Song noted that 37% of patients had received prior chemotherapy and 16% of patients who did not receive prior chemotherapy required either therapeutic or preventive treatments for bone marrow suppression. Thirty-one percent of patient received at least 1 life-prolonging therapy after treatment with radium-223. The investigators noted that some patients in this analysis received concomitant enzalutamide (31%) and concomitant bone health agents (47%). Most patients-77%-received at least 1 prior life-prolonging therapy such as enzalutamide (Xtandi 48%), abiraterone (Zytiga 45%), cabazitaxel (Jevtana 6%), docetaxel (25%) or sipuleucel-T (Provenge 24%). Between 5 and 6 injections of radium-223 were received by 69% of patients. In the analysis, 81% of patients had bone metastases only. In addition, they also monitored for patient-reported pain.Ī total of 498 patients (median age, 74 years) were enrolled in the REASSURE study from 2014 to 2017. Investigators primarily focused on short- and long-term safety including second primary malignancies and the incidence of bone marrow suppression. In this analysis, investigators focused on patients with confirmed metastatic castration-resistant prostate cancer from the US who were scheduled to receive treatment with radium-223. Song, MD, co-director of the prostate cancer multidisciplinary clinic and professor of radiation oncology and molecular radiation sciences at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, said during the poster presentation. ![]() “Our observations in this study show that radium-223 can be integrated into the treatment sequence for patients with (metastatic castration-resistant prostate cancer),” Daniel Y.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |